Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities
Despite progress in understanding ES biology, treatment options are limited, and prognosis remains poor. Further studies are needed, but the rarity of the disease limits opportunities for conducting dedicated clinical trials or broader molecular characterization.
Authors
- Paweł Sobczuk (ORCID: https://orcid.org/0000-0002-4103-1626)
- Cristina Gomez-Palmero
- César Serrano
Institutions
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Current Opinion in Oncology
- Published
- 2026-03-24
- DOI
- https://doi.org/10.1097/cco.0000000000001236
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00